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Abstract
Recent genome-wide association (GWA) studies described 95 loci controlling serum lipid levels. These common variants
explain ,25% of the heritability of the phenotypes. To date, no unbiased screen for gene–environment interactions for
circulating lipids has been reported. We screened for variants that modify the relationship between known epidemiological
risk factors and circulating lipid levels in a meta-analysis of genome-wide association (GWA) data from 18 population-based
cohorts with European ancestry (maximum N=32,225). We collected 8 further cohorts (N=17,102) for replication, and
rs6448771 on 4p15 demonstrated genome-wide significant interaction with waist-to-hip-ratio (WHR) on total cholesterol
(TC) with a combined P-value of 4.79610
29. There were two potential candidate genes in the region, PCDH7 and CCKAR,
with differential expression levels for rs6448771 genotypes in adipose tissue. The effect of WHR on TC was strongest for
individuals carrying two copies of G allele, for whom a one standard deviation (sd) difference in WHR corresponds to 0.19 sd
difference in TC concentration, while for A allele homozygous the difference was 0.12 sd. Our findings may open up
possibilities for targeted intervention strategies for people characterized by specific genomic profiles. However, more
refined measures of both body-fat distribution and metabolic measures are needed to understand how their joint dynamics
are modified by the newly found locus.
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Introduction
Serum lipids are important determinants of cardiovascular
disease and related morbidity [1]. The heritability of circulating
lipid levels is estimated to be 40%–60% and recent genome-wide
association (GWA) studies implicated a total of 95 loci associated
with serum high-density lipoprotein cholesterol (HDL-C), low-
density lipoprotein cholesterol (LDL-C), total cholesterol (TC), and
triglyceride (TG) levels [2]. Currently identified common variants
explain 10%–12% of the total variation in lipid levels, corre-
sponding to ,25% of the trait heritability [2].
Epidemiological risk factors, such as alcohol consumption,
smoking, physical activity, diet and body composition are known
to affect lipid levels [3–5]. These risk factors also show moderate to
high heritabilities, and over 120 loci with genome-wide significant
association have been identified (http://www.genome.gov/
26525384). To better understand the biological processes
modifying lipid levels, several twin studies [6–8] and candidate
gene studies [9–14] have tested for interactions between genes and
epidemiological risk factors.
Interactions between genes and modifiable risk factors might help
us develop new lifestyle interventions targeted to susceptible
individuals based on their genetic information. The effects of genetic
loci and risk factors have been studied widely separately, but to date
no GWA studies for interactions on lipids have been reported.
Results
We conducted a genome-wide screen for interactions between
2.5 million genetic markers and sex, lifestyle factors (smoking and
alcohol consumption), and body composition (BMI and WHR) in
association to serum lipid levels (TC, TG, HDL-C, and LDL-C) in
18 population-based cohorts (max N=32,225; Table S1A, Text
S1). We defined interaction as a departure from a linear statistical
model allowing for the additive main effects of both the SNP and
the epidemiological risk factor.
18 SNPs with suggestive interactions for at least one of the trait
– epidemiological factor combinations (P-value for the interaction
,10
26) in stage 1 analyses were taken forward to stage 2 analysis
in eight additional cohorts (max N=14,889; Table S1B, Text S1).
In inverse variance meta-analyses combining the results from stage
1 and stage 2 (Table S2), the interaction between rs6448771 in
chromosome 4p15 and WHR on TC (Figure 1) was statistically
genome-wide significant (stage 1 and 2 combined P=9.08610
29).
This interaction was tested in stage 3 in two further cohorts
(N=7,813; Table S1C, Text S1), which showed an effect to the
same direction. After combining results from all three stages (total
N=43,903), the P-value for interaction was 4.79610
29. The
association between WHR and TC was strongest for individuals
carrying two G alleles of rs6448771, for whom a one standard
deviation (sd) difference in WHR corresponds to 0.19 sd difference
(confidence interval 0.13–0.25) in TC concentration, while for
individuals homozygous for the A allele the difference was 0.12 sd
(confidence interval 0.09–0.16) (Table S3A, Figure S1). The effect
corresponds to 0.5% and 0.2% of the total variance explained in a
cohort of young individuals (YFS, mean age=37.6) and an old
cohort (HBCS, mean age=61.49), respectively. Additionally,
when looking at the effect of the SNP on TC in WHR tertiles,
the estimates differed in a way that the estimated SNP effect is
higher for the individuals with higher WHR (Table S3B). The
SNP did not have a direct effect on either TC or WHR (P=0.46
and P=0.51, respectively, Figure 1). The SNP rs6448771 is
located 249 kb downstream of the protocadherin 7 (PCDH7) gene.
Since the polymorphisms associated with complex phenotypes
often influence gene expression, we examined whether individuals
carrying different genotypes of rs6448771 have variation in their
transcript profiles. As WHR reflects adipose tissue function, we
selected 54 individuals from Finnish dyslipidemic families with
available fat biopsies and GWA data. We used linear regression to
find genes that were differentially expressed in adipose tissue
depending on the rs6448771 genotype. We found two potential
candidate genes with nominally significant cis-eQTL effects,
PCDH7 (P=0.027, distance from the rs6448771 250 kb) and
CCKAR (P=0.017, distance from the SNP 4.9 Mb). The region
with CCKAR has previously been linked with obesity [15].
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pathway analysis for genes with eQTL P-value,0.01 (both trans-
and cis-eQTLs). Among other diverse IPA-defined biological
functions, there was an eQTL association enrichment among
genes belonging to the ‘degradation of phosphatidylcholine’ (3
genes out of 6, P=6.64610
25, Benjamini-Hochberg corrected
P=0.0138) and ‘degradation of phosphatidic acid’ (4 genes out of
8, P=4.71610
24, B-H corrected P=0.0349) functions, which are
members of broader defined IPA categories ‘‘Lipid Metabolism’’
and ‘‘Carbohydrate Metabolism’’. These pathways were up-
regulated in individuals carrying the G allele of rs6448771,
possibly indicating a role for rs6448771 in lipid and carbohydrate
metabolism.
The associated SNP also shows evidence for interactions with
WHR on LDL-C (effect estimate for the interaction=0.03,
P=0.0016) and HDL-C (effect estimate=0.02, P=0.029) in our
stage 1 meta-analysis and after adjusting for TC no residual
interaction effect on LDL-C and a little on HDL-C remains
(P=0.834 and P=0.131 respectively) when testing in data subset.
Therefore we tested the SNP – WHR interaction also on a range
of lipoprotein subclasses measured using NMR metabonomics
platform [16] available in two cohorts (NFBC1966, N=4624
mean age=31.0; YFS, N=1889, mean age=37.6). The results
show that the SNP has a positive interaction effect on large HDL
particle concentration (combined effect for the interaction=0.538,
P=0.0186) and a negative effect on large very-low-density
lipoprotein (VLDL) particles (combined effect=20.466,
P=0.0291) and total triglycerides (combined effect=20.454,
P=0.0343) (Figure 2).
Discussion
Our genome-wide scan for interactions between SNP markers
and traditional epidemiological risk factors in population-based
random samples found a genome-wide significant locus,
rs6448771, modifying the relationship between WHR and TC.
The effect of WHR is estimated to be 64% stronger for individuals
carrying two copies of the G allele than for individuals carrying
two A alleles. The interaction explains around half a percent of the
TC variance that is in par with the main effects of the strongest
previously identified TC SNPs individually. This SNP also shows
similar interaction effects on a cascade of more detailed lipid
fractions suggesting broad involvement in lipid metabolism, which
was also suggested by our eQTL association enrichment analysis
with adipose tissue expression data.
The eQTL analysis pointed towards two potential candidate
genes in the region. The first one of these was protocadherin 7
(PCDH7) gene, which produces a protein that is thought to
function in cell-cell recognition and adhesion. The other candidate
gene, cholecystokinin A receptor (CCKAR) regulates satiety and
release of beta-endorphin and dopamine in the central and
peripheral nervous system. It has been previously shown that rats
with no expressed CCKARs developed obesity, hyperglycemia and
type 2 diabetes [17]. To test whether our eQTL finding was
adipose tissue specific, we ran the eQTL analysis for PCDH7 and
CCKAR in another dataset with genome wide expression data from
blood leukocytes (N=518) available. CCKAR could not be tested
due to its negligible expression in blood leukocytes, and no
association was found for the PCDH7 (P-value=0.284) gene most
likely indicating an adipose tissue specific eQTL for PCDH7 as a
function of rs6448771.
One interesting aspect of this study, given our large sample size,
is that only one signal achieved genome-wide significance, where
previously published lipid GWA studies have found close to a
hundred. Although power to detect interaction is typically lower
than for main effects, especially for rare exposures and SNPs,
several of the exposures considered here (such as WHR, BMI, and
gender) were common and available for a large proportion of the
study sample. This suggests that the contribution of two-way G6E
interactions to lipid levels, at least for the risk factors we examined,
is rather small, or that our current measures of risk factors may not
be robust enough for identifying interactions. More specific
measures of both phenotypes and interacting risk factors would
give better statistical power in future screens of G6E interactions.
Our findings allow us to draw several conclusions. First, to our
knowledge, this is the first time an interaction between a genetic loci
and a risk factor has been identified in a genome-wide scan using a
stringent statistical threshold for genome-wide significance. Second,
in our samples, rs6448771 modified the relationship between WHR
andTC, butwasnot associated witheitherWHRorTCalone.This
observation suggests that genome-wide screens for interactions may
be complementary to the current large-scale GWAS efforts for
finding main effects. Third, in addition to careful harmonization of
both risk factor data and phenotypes, large sample sizes are needed
to identify interactions. In our study, 43,903 samples were
combined to robustly identify the interaction. Our data, however,
suggest that the contribution of G6E interaction using current
phenotypes appears limited. Finally, from clinical point of view, the
interaction may open up possibilities for targeted intervention
strategies for people characterized by specific genomic profiles but
more refined measures of both body-fat distribution and metabolic
measures are needed to understand how their joint dynamics are
modified by the newly found locus.
Materials and Methods
Participating studies
18 studies, with a combined sample size of over 30,000
individuals, participated in the discovery phase of this analysis; 8
studies were available for replication with over 14,000 individuals.
In the discovery stage, only population-based cohorts not
Author Summary
Circulating serum lipids contribute greatly to the global
health by affecting the risk for cardiovascular diseases.
Serum lipid levels are partly inherited, and already 95 loci
affecting high- and low-density lipoprotein cholesterol,
total cholesterol, and triglycerides have been found. Serum
lipids are also known to be affected by multiple
epidemiological risk factors like body composition, life-
style, and sex. It has been hypothesized that there are loci
modifying the effects between risk factors and serum
lipids, but to date only candidate gene studies for
interactions have been reported. We conducted a ge-
nome-wide screen with meta-analysis approach to identify
loci having interactions with epidemiological risk factors
on serum lipids with over 30,000 population-based
samples. When combining results from our initial datasets
and 8 additional replication cohorts (maximum N=17,102),
we found a genome-wide significant locus in chromosome
4p15 with a joint P-value of 4.79610
29 modifying the
effect of waist-to-hip ratio on total cholesterol. In the area
surrounding this genetic variant, there were two genes
having association between the genotypes and the gene
expression in adipose tissue, and we also found enrich-
ment of association in genes belonging to lipid metabo-
lism related functions.
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defined epidemiological measures available, were included. In the
replication datasets, the NTR cohort was selected on the basis of
low risk for depression and the Genmets samples were selected for
metabolic syndrome. In further replication of rs6448771, the
EPIC cases were ascertained by BMI. Descriptive statistics for
Figure 1. Forest plot of main and WHR interaction effect sizes of rs6448771 on TC across the study cohorts. The circles in the plot are
positioned at the effect estimates, betas, and the size corresponds to the number of individuals. The whiskers correspond to the standard errors of
betas.
doi:10.1371/journal.pgen.1002333.g001
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(replication) and S1C (further replication). Brief descriptions of the
cohorts are provided in the Text S1 section ‘‘Short descriptions of
the cohorts’’.
Phenotype determination
Individuals were excluded from analysis if they were not of
European descent or were receiving lipid-lowering medication at
the time of sampling. TC, HDL-C, and TG concentrations were
measured from serum or plasma extracted from whole blood,
typically using standard enzymatic methods. LDL-C was either
directly measured or estimated using the Friedewald Equation
(LDL-C=TC – HDL-C – 0.456TG for individuals with
TG#4.52 mmol/l, samples with TG level higher than 4.52 were
discarded in the calculation of LDL-C) [18].
Covariates and epidemiological risk factors were ascertained at
the same time that blood was drawn for lipid measurements. BMI
was defined as weight in kilograms divided by the square of height
in meters. Waist circumference was measured at the mid-point
between the lower border of the ribs and the iliac crest; hip
circumference was measured at the widest point over the buttocks.
Waist-to-hip ratio was defined as the ratio of waist and hip
circumferences. Alcohol consumption and smoking habits were
determined via interviews and/or questionnaires. Both behaviors
were coded as dichotomous (abbreviations: ALC for drinker/
abstainer and SMO for current smoker/current non-smoker) and
semi-quantitative traits. Semi-quantitative alcohol usage (ALCq)
was based on daily consumption in grams (0: 0 g/day; 1: .0 and
#10 g/day; 2: .10 and #20 g/day; 3: .20 and #40 g/day; 4:
.40 g/day). Semi-quantitative smoking (SMOq) was assessed
based on the number of cigarettes per day (0: 0 cigarettes/day; 1:
.0 and #10 cigarettes/day; 2: .10 and #20 cigarettes/day; 3:
.20 and #30 cigarettes/day; 4: .30 cigarettes/day).
Genotyping and imputations
Affymetrix, Illumina or Perlegen arrays were used for
genotyping in the discovery cohorts. Each study filtered both
individuals and SNPs to ensure robustness for genetic analysis.
After quality control, these data were used to impute genotypes for
approximately 2.5 million autosomal SNPs based on the LD
patterns observed in the HapMap 2 CEU samples. Imputed
genotypes were coded as dosages, fractional values between 0 and
2 reflecting the estimated number of copies of a given allele for a
given SNP for each individual. Cohort specific details concerning
quality control filters, imputation reference sets and imputation
software are described in Table S4.
In silico replication
Replication cohorts utilized genome-wide imputed data, as
described above, where available. Details on the genotyping
methods implemented in the replication samples are described in
Table S4.
Serum NMR metabonomics, lipoprotein subclasses
Proton NMR spectroscopy was used to measure lipid,
lipoprotein subclass and particle concentrations in native serum
samples. NMR methods have been previously described in detail
[16,19]. Serum concentrations of total triglycerides (TG), total
cholesterol (TC) together with LDL-C and HDL-C were
determined. In addition, total lipid and particle concentrations
in 14 lipoprotein subclasses were measured. The measurements of
these subclasses have been validated against high-performance
liquid chromatography [20]. The subclasses were as follows:
chylomicrons and largest VLDL particles (particle diameters from
approx 75 nm upwards), five different VLDL subclasses: very large
VLDL (average particle diameter 64.0 nm), large VLDL
(53.6 nm), medium-size VLDL (44.5 nm), small VLDL
Figure 2. Lipoprotein subclass particle and key serum lipid concentration correlations with WHR for different genotypes of
rs6448771. The height of the bar is the meta-correlation between the lipoprotein particle concentration and waist-to-hip ratio, and the whiskers
correspond to standard error of the meta-correlation. The P-values have been taken from the interaction meta-analysis and only P-values,0.01 are
shown in the figure. The two cohorts in which the lipid particle concentrations were measured with NMR metabonomics platform were YFS and
NFBC1966 with combined number of samples of 6,500. XXL_VLDL: Chylomicrons and extremely large very low-density lipoprotein particles; XL: Very
large, L: large, M: Medium, S: Small, XS: Very small; VLDL: very low-density lipoprotein; IDL: intermediate-density lipoprotein; LDL: low-density
lipoprotein; HDL: High-density lipoprotein; TG: Triglycerides; TC: Total cholesterol.
doi:10.1371/journal.pgen.1002333.g002
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lipoprotein (IDL) (28.6 nm); three LDL subclasses: large LDL
(25.5 nm), medium-size LDL (23.0 nm), and small LDL
(18.7 nm); and four HDL subclasses: very large HDL (14.3 nm),
large HDL (12.1 nm), medium size HDL (10.9 nm), and small
HDL (8.7 nm).
Statistical methods
Triglyceride concentrations were natural log transformed prior
to analysis. BMI and WHR were transformed to normality using
inverse-normal transformation of ranks. For analyses where sex
was the epidemiological variable of interest, the phenotypes were
defined as the rank-inverse normal transformed residuals resulting
from the regression of the lipid measurement on age and age
2. For
the other analyses, the phenotypes were defined as the inverse
normal transformed residuals resulting from the regression of the
lipid measurement on age, age
2, and sex.
Associations between the transformed residuals and epidemio-
logical risk factors/SNPs were tested using linear regression
models under the assumption of an additive (allelic trend) model of
genotypic effect. The models regressed phenotypes on epidemio-
logical factor, SNP, and epidemiological factor6SNP terms
Transform residuals ðÞ *EzSNPzE|SNP
and tested if the effect for E6SNP was 0 using 1 df Wald tests. In
family-based cohorts, linear mixed modeling was implemented to
control for relatedness among samples [21]. Analysis software used
by the individual cohorts is described in Table S1A and S1B.
The interaction terms from the regression analyses were meta-
analyzed using inverse variance weighted fixed-effects models [22].
Prior to meta-analysis, genomic control correction factors (lGC)
[23], calculated from all imputed SNPs, were applied on a per-
study basis to correct for residual bias possibly caused by
population sub-structure. Meta-analyses were performed by two
independent analysts using METAL (http://www.sph.umich.edu/
csg/abecasis/Metal/index.html) and the R [24] package MetA-
BEL (part of the GenABEL suite, http://www.genabel.org/). All
results were concordant, reflecting a robust analysis. Results were
selected for in silico replication if the meta-analysis P-value was less
than 10
26. Results passing the threshold of suggestive genome-
wide association (P-value #5610
27) were selected for further
replication by direct genotyping.
The commonly accepted genome wide level of significance
(5610
28) reflects the estimated testing burden of one million
independent SNPs in samples of European ancestry [25]. To
address the multiple testing arising from testing interactions with
multiple risk factors, we set the genome wide significance threshold
to 5610
28/3=1.67610
28 corresponding to three principal
components explaining 97.8% of the total variation of the risk
factors (Table S5).
Pathway analysis. The functional analyses were generated
through the use of Ingenuity Pathways Analysis (Ingenuity
Systems, www.ingenuity.com).’’ The Functional Analysis
identified the biological functions and/or diseases that were most
significant to the data set. Molecules which met the P-value cutoff
of 0.01 for the rs6448771 – expression association in dataset of 54
Finnish individuals with both genotype and adipose tissue
expression data, and were associated with biological functions
and/or diseases in Ingenuity’s Knowledge Base were considered
for the analysis. Right-tailed Fisher’s exact test was used to
calculate a P-value determining the probability that each
biological function and/or disease assigned to that data set is
due to chance alone and Benjamini-Hochberg multiple test
correction [26] was applied.
Supporting Information
Figure S1 Effect of waist-to-hip ratio on total cholesterol as a
function of rs6448771 genotypes. The bars in the plot are the effect
estimates from three meta-analyzed linear models where total
cholesterol (TC) has been explained using waist-to-hip ratio
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dichotomous traits number of individuals with phenotype
present (%) is presented. TC: total cholesterol (mmol/l); HDL-
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density lipoprotein cholesterol( m m o l / l ) ;T G :t r i g l y c e r i d e s
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replication of the SNPs. Best SNP per locus having P-
value,1610
26 in the Stage 1 analysis combining 19 cohorts.
The bolded number is the genome-wide significant P-value. N:
number of individuals; SE: standard error of the effect estimate,
Beta; LDL-C: low-density lipoprotein cholesterol; TC: total
cholesterol; TG: triglycerides; HDL-C: high-density lipoprotein
cholesterol; ALC: alcohol usage (drinker/abstainer); WHR: waist-
to-hip ratio; BMI: body mass index; SMO: smoking (current/not);;
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#10 cigarettes/day; 2: .10 and #20 cigarettes/day; 3: .20 and
#30 cigarettes/day; 4: .30 cigarettes/day); ALCq: semi-quanti-
tative alcohol (0: 0 g/day; 1: .0 and #10 g/day; 2: .10 and
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Table S3 Effect of rs6448771 on total cholesterol (TC) by waist-
to-hip ratio (WHR) tertiles and effect of WHR on TC by SNP
genotype classes. Section A shows the combined effect of waist-to-
hip ratio (WHR) on total cholesterol (TC) stratified by the
rs6448771 genotype class from five Finnish cohorts (FINRISK,
NFBC1966, YFS, Genmets and HBCS, combined number of
individuals is 12,782) and section B shows the combined effect of
the SNP on TC stratified by WHR tertiles from the same cohorts.
The limit values for the waist-to-hip ratio (WHR) tertiles have
been calculated using WHR values from all five datasets. Both
analyses were ran using untransformed and standardized scales
and were adjusted with age, age
2 and sex. Beta: effect estimate; CI:
confidence interval.
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Component.
(DOC)
Genome-Wide Screen for G6E Interactions on Lipids
PLoS Genetics | www.plosgenetics.org 7 October 2011 | Volume 7 | Issue 10 | e1002333Text S1 Short descriptions of the cohorts and a full list of
acknowledgements.
(DOC)
Acknowledgments
This manuscript is dedicated in memory of Prof. Leena Peltonen whose
firm support and guidance had inspired this project immensely. The data
annotation, exchange and deposition in public archives have been
facilitated by the SIMBioMS platform (Krestyaninova et al, 2009).’’ A
full list of acknowledgments is provided in the Text S1.
Author Contributions
Conceived and designed the experiments: LP CMD YSA SR. Performed
the experiments: IS AI LCK. Analyzed the data: IS AI LCK PPL RPSM
ET JSR CL MM WI JJH VL PH IML TE ZK NWW MVS APS AJK.
Contributed reagents/materials/analysis tools: JSV MP TR AKP PS A ˚J
NS ACH TP IP AT FK AD FR GWM JBW MK TL NBF GW EJCG AP
MSS DW AM MS AGU AJ GN CW BHRW MRT MAK JK KOK DIB
NLP UG JFW IR HC PPP TDS JCMW JGE VS BAO OTR HEW CG
MRJ NGM AH. Wrote the paper: IS AI MIM CMD YSA SR.
References
1. Cooney M, Cooney H, Dudina A, Graham I (2010) Assesment of cardiovascular
risk. Curr Hypertens Rep 12: 384–393.
2. Teslovich T, Musunuru K, Smith A, Edmondson A, Stylianou I, et al. (2010)
Biological, clinical and population relevance of 95 loci for blood lipids. Nature
466: 707–713.
3. Gaziano J, Manson J (1996) Diet and heart disease. The role of fat, alcohol, and
antioxidants. Cardiol Clin 14: 69–83.
4. Bullen C (2008) Impact of tobacco smoking and smoking cessation on
cardiovascular risk and disease. Expert Rev Cardiovasc Ther 6: 883–895.
5. Kraus W, Slentz C (2009) Exercise training, lipid regulation, and insulin action:
a tangled web of cause and effect. Obesity (Silver Spring) 17 Suppl 3: S21–26.
6. Czerwinski S, Mahaney M, Rainwater D, Vandeberg J, MacCluer J, et al. (2004)
Gene by smoking interaction: evidence for effects on low-density lipoprotein size
and plasma levels of triglyceride and high-density lipoprotein cholesterol. Hum
Biol 76: 863–876.
7. Greenfield J, Samaras K, Jenkins A, Kelly P, Spector T, et al. (2004) Do gene-
environment interactions influence fasting plasma lipids? A study of twins.
Eur J Clin Invest 34: 590–598.
8. Wang X, Ding X, Su S, Spector T, Mangino M, et al. (2009) Heritability of
insulin sensitivity and lipid profile depend on BMI: evidence for gene-obesity
interaction. Diabetologia 52: 2578–2584.
9. Sentı ´ M, Aubo C, Bosch M (1998) The relationship between smoking and
triglyceride-rich lipoproteins is modulated by genetic variation in the
glycoprotein IIIa gene. Metabolism 47: 1040–1041.
10. Sentı ´ M, Elosua R, Toma ´s M, Sala J, Masia ´ R, et al. (2001) Physical activity
modulates the combined effect of a common variant of the lipoprotein lipase
gene and smoking on serum triglyceride levels and high-density lipoprotein
cholesterol in men. Hum Genet 109: 385–392.
11. Junyent M, Tucker K, Smith C, Garcia-Rios A, Mattei J, et al. (2009) The effects
of ABCG5/G8 polymorphisms on plasma HDL cholesterol concentrations
depend on smoking habit in the Boston Puerto Rican Health Study. J Lipid Res
50: 565–573.
12. Corbex M, Poirier O, Fumeron F, Betoulle D, Evans A, et al. (2000) Extensive
association analysis between the CETP gene and coronary heart disease
phenotypes reveals several putative functional polymorphisms and gene-
environment interaction. Genet Epidemiol 19: 64–80.
13. Brand-Herrmann S, Kuznetsova T, Wiechert A, Stolarz K, Tikhonoff V, et al.
(2005) Alcohol intake modulates the genetic association between HDL
cholesterol and the PPARgamma2 Pro12Ala polymorphism. J Lipid Res 46:
913–919.
14. Marques-Vidal P, Bongard V, Ruidavets J, Fauvel J, Hanaire-Broutin H, et al.
(2003) Obesity and alcohol modulate the effect of apolipoprotein E
polymorphism on lipids and insulin. Obes Res 11: 1200–1206.
15. Arya R, Duggirala R, Jenkinson C, Almasy L, Blangero J, et al. (2004) Evidence
of a novel quantitative-trait locus for obesity on chromosome 4p in Mexican
Americans. Am J Hum Genet 74: 272–282.
16. Inouye M, Kettunen J, Soininen P, Silander K, Ripatti S, et al. (2010)
Metabonomic, transcriptomic, and genomic variation of a population cohort.
Mol Syst Biol Dec 21: 441.
17. Moran T, Katz L, Plata-Salaman C, Schwartz G (1998) Disordered food intake
and obesity in rats lacking cholecystokinin A receptors. Am J Physiol 273:
R618–R625.
18. Friedewald W, Levy R, Fredrickson D (1972) Estimation of the concentration of
low-density lipoprotein cholesterol in plasma, without use of the preparative
ultracentrifuge. Clin Chem 18: 499–502.
19. Soininen P, Kangas A, Wu ¨rtz P, Tukiainen T, Tynkkynen T, et al. (2009) High-
throughput serum NMR metabonomics for cost-effective holistic studies on
systemic metabolism. Analyst 134: 1781–1785.
20. Okazaki M, Usui S, Ishigami M, Sakai N, Nakamura T, et al. (2005)
Identification of unique lipoprotein subclasses for visceral obesity by component
analysis of cholesterol profile in high-performance liquid chromatography.
Thromb Vasc Biol 25: 578–584.
21. Aulchenko Y, Struchalin M, van Duijn C (2010) ProbABEL package for
genome-wide association analysis of imputed data. BMC Bioinformatics 16: 134.
22. de Bakker P, Ferreira M, Jia X, Neale B, Raychaudhuri S, et al. (2008) Practical
aspects of imputation-driven meta-analysis of genome-wide association studies.
Hum Mol Genet 17: R122–128.
23. Devlin B, Roeder K, Wasserman L (2001) Genomic control, a new approach to
genetic-based association studies. Theor Popul Biol 600: 155–166.
24. R Development Core Team: R: A language and environment for statistical
computing, Access date: 2010 Dec 13, http://R-project.org.
25. Pe’er I, Yelensky R, Altshuler D, Daly M (2008) Estimation of the multiple
testing burden for genomewide association studies of nearly all common variants.
Genet Epidemiol 32: 381–385.
26. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical
and powerful approach to multiple testing. J Roy Static Soc Ser B 57: 289–300.
Genome-Wide Screen for G6E Interactions on Lipids
PLoS Genetics | www.plosgenetics.org 8 October 2011 | Volume 7 | Issue 10 | e1002333